AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
ridaforolimus 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| immunosuppressants, rapamycin derivatives | 4778 | 572924-54-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an mTOR inhibitor for the treatment of cancer
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 3.20 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 46.30 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.028 | High | 0.85 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 8.414 | High | 0.85 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 23.227 | 10^-6 cm/s | High | 0.85 |
| dh-clint | Dog hepatocyte intrinsic clearance | 90.573 | uL/min/10^6 cells | High | 0.85 |
| dppb | Dog plasma protein binding (% unbound) | 0.910 | % | High | 0.85 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 3.090 | % | High | 0.85 |
| herg | hERG pIC50 | 4.490 | pIC50 | High | 0.85 |
| hh-clint | Human hepatocyte intrinsic clearance | 25.704 | uL/min/10^6 cells | High | 0.85 |
| hlm-clint | Human liver microsomal intrinsic clearance | 230.675 | uL/min/mg protein | High | 0.85 |
| hppb | Human plasma protein binding (% unbound) | 1.780 | % | High | 0.85 |
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 20 | |||
| kinase-selectivity-class | GRK2 | 1 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 40.644 | High | 0.90 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 8.831 | High | 0.85 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 28.249 | High | 0.85 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.690 | High | 0.85 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 83.753 | High | 0.85 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 0.90 | |
| pppb | Pig plasma protein binding (% unbound) | 1.570 | % | High | 0.85 |
| rat-kpuu-brain | Rat brain Kpuu | 0.005 | % | High | 0.87 |
| rh-clint | Rat hepatocyte intrinsic clearance | 55.463 | uL/min/10^6 cells | High | 0.85 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 5.920 | % | High | 0.85 |
| rppb | Rat plasma protein binding (% unbound) | 1.890 | % | High | 0.85 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 32.885 | uM | High | 0.85 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01EG03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Mammalian target of rapamycin (mTOR) kinase inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:68481 | mTOR inhibitor |
Related Drugs by ATC class:
L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.5 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Serine/threonine-protein kinase mTOR | Kinase | INHIBITOR | IC50 | 9.70 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Kinase | Kd | 5.90 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D08900 | KEGG_DRUG |
| CHEBI:82677 | CHEBI |
| CHEMBL2103839 | ChEMBL_ID |
| C515074 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7884 | IUPHAR_LIGAND_ID |
| DB06233 | DRUGBANK_ID |
| 48Z35KB15K | UNII |
| C2713007 | UMLSCUI |
| 8822 | INN_ID |
| 11520894 | PUBCHEM_CID |
Pharmaceutical products:
None